HIGHLIGHTS
- who: Tianyuan Xie and collaborators from the Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Life Science and Technology, China Pharmaceutical University, Longmian Road, Nanjing, China have published the research: Emerging Roles of RNF168 in Tumor Progression, in the Journal: Molecules 2023, 28, x FOR PEER REVIEW of 12/08/2022
- what: Future work can be carried out to explore RNF168 inhibitor or activator, which may facilitate the development of RNF168-targeted therapy for tumors or other related diseases.
- future: The role of RNF168 in BRCA1 mutant tumor cells needs further study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.